SCHEMBL4908161

SCHEMBL4908161

CC(C)(CCn1cnc2cc(C(=O)O)ccc21)NC[C@H](OC(=O)C(F)(F)F)c1cccc(NS(=O)(=O)c2ccccc2)c1

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NR1I2 O75469 5/20 0.41
HPGD P15428 2/20 0.40
ADRB3 P13945 1/20 0.38
ALDH1A1 P00352 2/20 0.38
KMT2A Q03164 2/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37
HTT P42858 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
OPRM1 P35372 1/20 0.37
OPRD1 P41143 1/20 0.37
MEN1 O00255 1/20 0.36
PPARG P37231 1/20 0.36
IDH1 O75874 1/20 0.36
KEAP1 Q14145 1/20 0.36
NFE2L2 Q16236 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4918960 0.94 ADRB3 (0.38) NR1I2HPGDADRB3ALDH1A1KMT2A
SCHEMBL4639786 0.90 ADRB3 (0.42) NR1I2HPGDADRB3ALDH1A1KMT2A
SCHEMBL4605628 0.90 ADRB3 (0.42) NR1I2HPGDADRB3ALDH1A1KMT2A
SCHEMBL4895290 0.90 HPGD (0.38) NR1I2HPGDADRB3ALDH1A1KMT2A
SCHEMBL4605863 0.90 NR1I2 (0.40) NR1I2HPGDADRB3ALDH1A1KMT2A
Trifluoroacetic Acid SCHEMBL4644337 0.89 ADRB3 (0.42) NR1I2HPGDADRB3ALDH1A1KMT2A
SCHEMBL4892535 0.88 ADRB3 (0.38) NR1I2HPGDADRB3ALDH1A1KMT2A
SCHEMBL1379764 0.88 NR1I2 (0.44) NR1I2HPGDADRB3ALDH1A1KMT2A
SCHEMBL4914684 0.88 NR1I2 (0.44) NR1I2HPGDADRB3ALDH1A1KMT2A
SCHEMBL4918863 0.87 KEAP1 (0.38) NR1I2HPGDADRB3ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080103138-A1 Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-05-01 US disclosed
US-20070112033-A1 N-(3-{2-[3-(6-amino-benzimidazol-1-yl)-1,1-dimethyl-propylamino]-1-hydroxy-ethyl}-phenyl)-benzenesulphonamide; beta(3)-Adrenoceptor agonists; antidiabetic, obesity, insulin resistance BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080103138-A1 Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions ADRB1, ADRB3, ADRB2 NR1I2 307/4885HPGD 1119/4885ADRB3 2/4885
US-20070112033-A1 N-(3-{2-[3-(6-amino-benzimidazol-1-yl)-1,1-dimethyl-propylamino]-1-hydroxy-ethyl}-phenyl)-benzenesulphonamide; beta(3)-Adrenoceptor agonists; antidiabetic, obesity, insulin resistance ADRB3, ADRB1, ADRA1B NR1I2 103/4885HPGD 2957/4885ADRB3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.